- Home
- XPON vs RNAZ Comparison
XPON vs RNAZ Comparison
Compare XPON & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPON | RNAZ |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XPON | RNAZ |
|---|---|---|
| Price | $0.76 | $9.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 2.0M | 139.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,417,947.00 | N/A |
| Revenue This Year | $61.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 109.37 | N/A |
| 52 Week Low | $0.60 | $6.08 |
| 52 Week High | $5.50 | $399.00 |
Technical Indicators
Market Signals| Indicator | XPON | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 36.03 | 55.88 |
| Support Level | $0.80 | $8.35 |
| Resistance Level | $1.11 | $12.60 |
| Average True Range (ATR) | 0.08 | 0.96 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 6.74 | 48.86 |
Price Performance
Historical ComparisonAbout XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.